| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Atherosclerosis and Lipoproteins |
From the Department of Medicine, Division of Medical Genetics (G.P.J., L.A.M., R.W., V.H.B., R.J.R., C.E.F.), and the Departments of Epidemiology (G.P.J.), Neurology (G.D.S.), Genomic Sciences (G.P.J., C.E.F.), and Biostatistics (P.J.H.), University of Washington, and the Puget Sound Veterans Affairs Health Care Systems (N.T.T., L.A.M., R.W., G.D.S., T.S.H.), Seattle, Wash.
Reprint requests to Gail P. Jarvik, MD, PhD, University of Washington Medical Center, Division of Medical Genetics, Box 357720, Seattle, WA 98195. E-mail pair{at}u.washington.edu
Objective Paraoxonase (PON1), an esterase physically associated with high density lipoprotein, has been shown to inhibit atherogenic low density lipoprotein and high density lipoprotein oxidation. PON1 activity appears to be primarily under genetic control with some environmental modification and is a predictor of vascular disease. Vitamins C and E, dietary antioxidants, scavenge free-oxygen radical products that may depress PON1 activity. Therefore, we evaluated the relationship between dietary vitamin C and E intake and PON1 activity.
Methods and Results The vitamin C and E intakes of male white subjects (n=189) were estimated by using a standardized food frequency survey. With covariates, vitamin C or E intakes were found to be significant positive predictors of PON1 activity for the hydrolysis of paraoxon and diazoxon with the use of linear regression. Smoking and use of statins were independent predictors of PON1 activity.
Conclusions PON1 activity, which is primarily genotype dependent, varies with antioxidant vitamins, cigarette smoking, and statin drug use. Because PON1 activity is a better predictor of vascular disease than is the currently described genetic variation in PON1, further studies of the environmental influences on PON1 activity and additional PON1 genetic variants are warranted.
Key Words: antioxidants genetics vitamins paraoxonase smoking
This article has been cited by other articles:
![]() |
J. J. Regieli, J. W. Jukema, P. A. Doevendans, A. H. Zwinderman, J. J. Kastelein, D. E. Grobbee, and Y. van der Graaf Paraoxonase variants relate to 10-year risk in coronary artery disease: impact of a high-density lipoprotein-bound antioxidant in secondary prevention. J. Am. Coll. Cardiol., September 29, 2009; 54(14): 1238 - 1245. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L Rainwater, M. C Mahaney, J. L VandeBerg, and X. L. Wang Vitamin E dietary supplementation significantly affects multiple risk factors for cardiovascular disease in baboons Am. J. Clinical Nutrition, September 1, 2007; 86(3): 597 - 603. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Mutch, A. K. Daly, and F. M. Williams The Relationship between PON1 Phenotype and PON1-192 Genotype in Detoxification of Three Oxons by Human Liver Drug Metab. Dispos., February 1, 2007; 35(2): 315 - 320. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Ferre, J. Camps, J. Marsillach, B. Mackness, M. Mackness, B. Coll, M. Tous, and J. Joven Comparison of Paraoxonase 1 Measurements in Serum and in Lithium-Heparin-Anticoagulated Plasma Samples Clin. Chem., May 1, 2005; 51(5): 922 - 923. [Full Text] [PDF] |
||||
![]() |
T. M. van Himbergen, M. Roest, J. de Graaf, E. H. J. M. Jansen, H. Hattori, J. J. P. Kastelein, H. A. M. Voorbij, A. F. H. Stalenhoef, and L. J. H. van Tits Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia J. Lipid Res., March 1, 2005; 46(3): 445 - 451. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. F Hernndez, B. Mackness, L. Rodrigo, O. Lopez, A. Pla, F. Gil, P. N Durrington, G. Pena, T. Parron, J. L Serrano, et al. Paraoxonase activity and genetic polymorphisms in greenhouse workers with long term pesticide exposure Human and Experimental Toxicology, November 1, 2003; 22(11): 565 - 574. [Abstract] [PDF] |
||||
![]() |
R. J. Hillstrom, A. K. Yacapin-Ammons, and S. M. Lynch Vitamin C Inhibits Lipid Oxidation in Human HDL J. Nutr., October 1, 2003; 133(10): 3047 - 3051. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Ferre, J. Camps, J. Fernandez-Ballart, V. Arija, M. M. Murphy, S. Ceruelo, E. Biarnes, E. Vilella, M. Tous, and J. Joven Regulation of Serum Paraoxonase Activity by Genetic, Nutritional, and Lifestyle Factors in the General Population Clin. Chem., September 1, 2003; 49(9): 1491 - 1497. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. S. Ford, A. H. Mokdad, W. H. Giles, and D. W. Brown The Metabolic Syndrome and Antioxidant Concentrations: Findings From the Third National Health and Nutrition Examination Survey Diabetes, September 1, 2003; 52(9): 2346 - 2352. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. G. Cabana, C. A. Reardon, N. Feng, S. Neath, J. Lukens, and G. S. Getz Serum paraoxonase: effect of the apolipoprotein composition of HDL and the acute phase response J. Lipid Res., April 1, 2003; 44(4): 780 - 792. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2002 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |